Coronavir

Novel Coronavirus SARS-CoV-2

Coronavir is an anti-viral drug approved in Russia for the treatment of COVID-19. Little is known of this drug, except for the information released by its developer R-Pharm.[1][2]

By the description provided to the press, coronavir seems to be an inhibitor of SARS-CoV-2 RNA polymerase, similar to other antiviral nucleotide analogues such as remdesivir.[1] The drug appears to be based on favipiravir, a drug developed in Japan.[3]

Coronavir was approved for use in Russia in hospitals in July 2020, and in September 2020 it received approval for prescription sales for outpatient use.[3]

See also

References

  1. 1 2 "Russian firm gets approval for drug said to block coronavirus replication". July 8, 2020 – via in.reuters.com.
  2. ↑ "Russia approves R-Pharm's Coronavir for Covid-19 treatment". Pharmaceutical Technology. 9 July 2020. Retrieved 21 July 2020.
  3. 1 2 Reuters Staff (2020-09-18). "Russia approves first COVID-19 prescription drug for sale in pharmacies". Reuters (in French). Retrieved 2020-09-20.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.